VRDN实时信号 | 通过Getagraph.com最大化利润

购买 107728 min ago

@ $18.37

发出时间: 15 Feb 2024 @ 03:55

回报率: -31.30%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: 1.83 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 23:24):

Stats
今日成交量	135 013
平均成交量	899 317
市值	792.13M
EPS	$0 ( 2024-03-13 )
下一个收益日期	( $-1.070 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.38
ATR14	$0.0270 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Fairmount Funds Management Llc	Buy	5 859	Common Stock
2024-03-28	Fairmount Funds Management Llc	Buy	21 999	Series A Non-Voting Convertible Preferred Stock
2024-03-28	Fairmount Funds Management Llc	Sell	5 859	Common Stock
2024-03-28	Fairmount Funds Management Llc	Sell	21 999	Series A Non-Voting Convertible Preferred Stock
2024-02-12	Tousignant Jennifer	Buy	0

INSIDER POWER
58.79
Last 95 transactions
Buy: 5 352 885 \| Sell: 1 550 540

音量相关性

長: -0.19 (neutral)

短: -0.42 (neutral)

Signal:(42.735) Neutral

Viridian Therapeutics, 相关性

10 最正相关
TBNK	0.946
RGLD	0.946
MCHI	0.941
ISEM	0.939
HCM	0.938
IMVT	0.938
QFIN	0.935
PGJ	0.933
WLFC	0.932
ROIV	0.924

10 最负相关
LLNW	-0.934
PCRX	-0.918
SFET	-0.915
SWAV	-0.913
ASPS	-0.913
GRIN	-0.907
NKTX	-0.906
RTPY	-0.895
LAWS	-0.893
LNSR	-0.889

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Viridian Therapeutics, 相关性 - 货币/商品

0.32
( neutral )

0.45
( neutral )

0.00
( neutral )

0.03
( neutral )

0.76
( moderate )

0.56
( weak )

Viridian Therapeutics, 财务报表

Annual	2023
营收:	$314 000
毛利润:	$-1.01M (-321.02 %)
EPS:	$-5.31

FY	2023
营收:	$314 000
毛利润:	$-1.01M (-321.02 %)
EPS:	$-5.31

FY	2022
营收:	$1.77M
毛利润:	$1.02M (57.39 %)
EPS:	$-3.91

FY	2021
营收:	$2.96M
毛利润:	$0.00 (0.00 %)
EPS:	$-6.66

Financial Reports:

No articles found.

Viridian Therapeutics,

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.